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Context. Patients with post-stroke spasticity (PSS) commonly experience pain in affected limbs, which may impact quality
of life.
Objectives. To assess onabotulinumtoxinA for pain in patients with PSS from the BOTOX Economic Spasticity Trial, a
multicenter, randomized, double-blind, placebo-controlled trial.
Methods. Patients with PSS (N ¼ 273) were randomized to 22- to 34-week double-blind treatment with
onabotulinumtoxinA þ standard care (SC) or placebo injection þ SC and were eligible to receive open-label
onabotulinumtoxinA up to 52 weeks. Assessments included change from baseline on the 11-point pain numeric rating scale,
proportion of patients with baseline pain $4 achieving $30% and $50% improvement in pain, and pain interference with
work at Week 12, end of double-blind treatment, and Week 52.
Results. At baseline, most patients (74.3%) experienced pain and 47.4% had pain $4 (pain subgroup). Mean pain
reduction from baseline at Week 12 was significantly greater with onabotulinumtoxinA þ SC (0.77, 95% CI 1.14 to 0.40)
than placebo þ SC (0.13, 95% CI 0.51 to 0.24; P < 0.05). Higher proportions of patients in the pain subgroup achieved
$30% and $50% reductions in pain at Week 12 with onabotulinumtoxinA þ SC (53.7% and 37.0%, respectively) compared
with placebo (28.8% and 18.6%, respectively; P < 0.05). Reductions in pain were sustained through Week 52. Compared with
placebo þ SC, onabotulinumtoxinA consistently reduced pain interference with work.
Conclusion. This is the first randomized, placebo-controlled trial demonstrating statistically significant and clinically
meaningful reductions in pain and pain interference with work with onabotulinumtoxinA in patients with PSS. J Pain
Symptom Manage 2016;52:17e26.  2016 The Authors. Published by Elsevier Inc. on behalf of American Academy of Hospice and
Palliative Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Pain prevalence varies widely (10%e70%) among
post-stroke patients.1e4 Several mechanisms may
contribute to this range (e.g., peripheral nerve
damage, soft tissue trauma, central post-stroke pain,
complex regional pain syndrome5e8). Spasticity and
pain are factors contributing to ‘‘learned non-use’’ of
the affected limb and are often disabling, interfering
with daily activities, sleep, walking, physiotherapy,
leisure activities, and ultimately affecting patients’
quality of life.9e11
In randomized, double-blind, placebo-controlled
trials, onabotulinumtoxinA has been shown to signifi-
cantly reduce excess muscle tone and decrease
disability among patients with upper-limb spas-
ticity,12,13 and to further reduce spasms and improve
gait in patients with lower-limb spasticity.14,15 Onabo-
tulinumtoxinA is effective at reducing pain in patients
with cervical dystonia and chronic migraine.16
Prospective open-label studies have shown that onabo-
tulinumtoxinA can reduce pain in patients with post-
stroke spasticity (PSS).8,17,18 However, the efficacy of
onabotulinumtoxinA in reducing pain in patients
with PSS has not been demonstrated in a large, ran-
domized, placebo-controlled study.
The BOTOX Economic Spasticity Trial (BEST)
was a prospective clinical trial designed to compare
the efficacy of onabotulinumtoxinA or placebo
(in addition to standard care [SC]) in helping patients
with PSS achieve their personal functional goals.19
Here, we present results from BEST comparing the
effectiveness of onabotulinumtoxinA þ SC versus
placebo þ SC on pain.Methods
Study Design and Patients
Details regarding the study design have been
published.19,20 Briefly, BEST was a prospective, multi-
center, randomized, double-blind, placebo-controlled,
Phase 3b study in Germany, Sweden, the United
Kingdom, and Canada (NCT-00549783). Patients
aged 18 to 85 years, with PSS ($1 item on the REsis-
tance to PAssive movement Scale [REPAS]21 with a
spasticity score $1 across the relevant joints for which
the primary outcome was defined) were randomized
to onabotulinumtoxinA (BOTOX, Allergan Plc,
Dublin, Ireland) þ SC or placebo þ SC. An optional
second dose was administered not earlier than
12 weeks after the first injection. The double-blind
phase lasted for 22 to 34 weeks, depending on the
timing of the second injection, followed by an open-
label extension through Week 52. Onabotulinumtoxi-
nA dosing was determined by the investigator based
on the treatment goal for the patient for the selectedmuscle. The primary efficacy end point was the attain-
ment of the principal active functional goal as assessed
by the physician at 10 weeks after the second injection
(or Week 24 if no second injection). Other end points
included secondary functional goal achievement and
effect of onabotulinumtoxinA on patient-reported
outcomes (e.g., pain, health-related quality of life
[HRQoL]).19 The BEST study complied with Good
Clinical Practice. Patients provided written informed
consent.Pain Assessments
Pain, when the affected limbs were stretched in a stan-
dardized manner, was assessed using the 11-point pain
numeric rating scale (PNRS; 0 ¼ no pain to 10 ¼ pain
asbadas canbe imagined)atbaseline,Week12,10weeks
after theoptional second injection (orWeek 24 if no sec-
ond injection), and Week 52. The stretch for assessing
pain with the PNRS was performed according to the
manual of the REPAS scale21 and in a predefined
manner with respect to limb andbodypositionof thepa-
tient as well as the extent and speed ofmovement. A sin-
gle investigator in each study center performed all the
stretching and associated pain measurements with the
PNRS over the course of the study. Successive stretching
for the PNRS rating was usually performed twice (at
most three times if necessary) according to the REPAS
instructions on the most affected joint of the affected
arm (i.e., shoulder [external rotation, flexion, abduc-
tion], elbow [flexion, extension], forearm[supination],
or wrist and finger [extension]) or leg (i.e., hip
[external rotation], knee [flexion, extension], or foot
[dorsiflexion, eversion/pronation]). A reduction of
30% in thePNRSrepresents a clinically importantdiffer-
ence in patients with chronic pain.22 The extent of work
interference resulting frompain wasmeasuredwith one
item on the Medical Outcomes Study Short Form-12
(SF-12) health survey.23 Using this item, patients were
asked to rate the extent to which pain interfered with
their normal work (including work outside the home/
housework) during the past four weeks on a five-point
scale (ranging from 1 ¼ not at all, to 5 ¼ extremely,
with three being moderate work interference).Statistical Analyses
Analyses were not prespecified in the protocol and
were performed in the intent-to-treat (ITT) population
(all randomized patients who received study medica-
tion at baseline). A subgroup analysis included patients
with baseline pain intensity $4 (‘‘pain subgroup’’),
which represents moderate (PNRS range 4e6) or se-
vere pain (range 7e10).22,24,25 Mean (95% CI) change
from baseline in PNRS was evaluated at Week 12,
10 weeks after the optional second injection (or
Week 24 if no second injection), and at Week 52 in
Table 1
Baseline Demographic and Disease Characteristics
Characteristic
OnabotulinumtoxinA þ
SC (n ¼ 139)
Placebo þ SC
(n ¼ 134)
Gender, n (%)
Female 54 (39) 59 (44)
Age
Mean (range), yrs 62 (23e81) 61 (27e82)
<65, n (%) 73 (53) 81 (60)
Severity of stroke,a n (%)
Mild 9 (7) 5 (4)
Moderate 99 (71) 97 (72)
Severe 31 (22) 32 (24)
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ance,26 with baseline pain as a covariate. In the pain
subgroup, the proportions of patients achieving
$30% and $50% reduction in pain (from baseline)
were compared between treatment arms using the c2
or Fisher exact tests with small samples. The propor-
tion of patients with moderate-to-extreme work inter-
ference because of pain at baseline (SF-12 item
score ¼ 3e5) achieving a $1- or $2-point reduction
on this scale were assessed between treatments at these
time points. Missing pain scores were not imputed.
Within-group change in the proportion of patients
achieving reductions on the PNRS or SF-12 item
response was based on the McNemar test.27 A two-
sided P-value of #0.05 was considered statistically
significant.
Exploratory Analyses
Patients identified a set of passive secondary goals,
mostly related to symptom relief (see previous publica-
tion20). In an exploratory analysis, the subset of pa-
tients who chose pain relief as a secondary goal and
the percentages of patients who achieved these goals
based on patients’ assessments on the goal attainment
scale (GAS) were compared between treatments. Goal
attainment related to pain relief specifically at the
shoulder or lower limb was evaluated. Pearson’s corre-
lation coefficient (r) was used to examine the associa-
tion between change in pain scores and changes in
REPAS scores at Weeks 12 and 52.Time since stroke
Mean (range),
months
47 (3e256) 46 (3e408)
>12 months, n (%) 87 (63) 85 (63)
Treated limbs, n (%)
Upper limb only 36 (26) 43 (32)
Lower limb only 36 (26) 34 (25)
Upper and lower
limbs
67 (48) 57 (43)
Severity of spasticity,b n (%)
Mild 5 (4) 3 (2)
Moderate 97 (70) 101 (75)
Severe 37 (27) 30 (22)
PNRS score
Mean (SD) 3.4 (3.1) 3.7 (3.0)
PNRS $4, n (%) 60 (43) 69 (51)
Pain interference with
work, n (%)
48 (34.5) 64 (47.8)
Concomitant medications,
n (%)
Oral antispasticity
agents
28 (20.1) 30 (22.4)
NSAIDs 20 (14.4) 31 (23)
Opioid analgesics 14 (10) 23 (17)
Neuropathic pain
drugs
19 (13.7) 14 (10.5)
Antidepressants 48 (34.5) 62 (46.3)c
Anti-anxiety agents 25 (18.0) 21 (15.7)
SC ¼ standard care; PNRS ¼ pain numeric rating scale.
aDetermined by physician assessment.
bDefined as follows: Mild ¼ baseline REPAS Ashworth score (AS) <2 in all
joints. Moderate ¼ baseline AS 2-3 in at least one joint and AS of 4 in
none. Severe ¼ baseline AS of 4 in at least one joint.
cP < 0.05 versus onabotulinumtoxinA þ SC.Results
Baseline Characteristics
The ITT population included 273 patients; disposi-
tion and treatment characteristics were previously re-
ported.20 Baseline characteristics were comparable
between groups (Table 1); mean age was 61 years,
and 41.4% of patients were female. As part of SC,
many patients were taking concomitant medications
(e.g., oral antispasticity agents, nonsteroidal anti-
inflammatory drugs, opioids, neuropathic pain medi-
cations, anti-anxiety agents). Most patients (74.3%,
202/272) had some baseline pain (PNRS > 0);
47.4% (129/272) had a baseline pain score $4. The
mean pain scores generally increased with spasticity
severity from mild to severe, although the correlation
between PNRS and REPAS scores was low
(r ¼ 0.296). At baseline, 34.5% of patients in the
onabotulinumtoxinA þ SC and 47.8% of those in
the placebo þ SC group reported moderate-to-
extreme work interference caused by pain
(P < 0.05). The median first and optional second in-
jection doses were 340U and 365U of study drug,
respectively (double-blind, ITT population). Overall,224 patients received open-label onabotulinumtoxinA
(n ¼ 113 initially randomized to onabotulinumtoxinA;
n ¼ 111 initially randomized to placebo).Mean Pain Improvement: Double-Blind Phase
At Week 12, the mean reduction in pain from base-
line was greater with onabotulinumtoxinA þ SC
(0.77, 95% CI 1.14 to 0.40) versus
placebo þ SC (0.13, 95% CI 0.51 to 0.24)
(Table 2; Fig. 1; P < 0.05 [ITT]). At Week 24 (for pa-
tients who received one injection) or 10 weeks after
the second injection, patients in the
onabotulinumtoxinA þ SC group continued to have
greater reductions in pain score from baseline
(0.78, 95% CI 1.22 to 0.34) versus
placebo þ SC (0.13, 95% CI 0.58 to 0.31)
(Table 2; Fig. 1; P < 0.05).
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were generally higher than in the ITT population, and
were greater with onabotulinumtoxinA þ SC (2.10,
95% CI 2.69 to 1.51) than placebo þ SC (1.21,
95% CI 1.77 to 0.65) (P < 0.05) at Week 12. At
Week 24 or 10 weeks after the second injection, pain
reduction with onabotulinumtoxinAþ SC was numeri-
cally but not significantly greater than placebo þ SC
(Table 2; P ¼ 0.145).
Patients Achieving $30% and $50% Reduction in
Pain From Baseline: Double-Blind Phase
In the pain subgroup, more patients receiving
onabotulinumtoxinA þ SC (53.7% [29/54] and
37.0% [20/54], respectively) achieved clinically mean-
ingful reductions in pain of $30% and $50% at Week
12 compared with placebo þ SC (28.8% [17/59] and
18.6% [11/59], respectively; Fig. 2; P < 0.05). At Week
24 or 10 weeks after the second injection, the propor-
tions of patients who achieved $30% and $50% re-
ductions from baseline in pain were also significantly
higher with onabotulinumtoxinA þ SC (55.8% and
44.2%, respectively) than placebo þ SC (35.0% and
28.3%, respectively) (Fig. 2; P < 0.05 for differences
between treatment arms only for $30% reduction).
Among patients of the pain subgroup who experi-
enced $30% improvement in pain scores at Week 12,
73.1% (19/26) in the onabotulinumtoxinAþ SC group
compared with 37.5% (6/16) in the placebo þ SC
group maintained this level of response at Week
24/10 weeks after the second injection (P< 0.05). Simi-
larly, in the onabotulinumtoxinA þ SC arm, 72.2% of
pain subgroup patients who achieved a$50% improve-
ment in pain at Week 12 maintained that level of
response through the end of double-blind, as
compared with 50.0% of those receiving placebo þ SC
(P ¼ 0.412).
Mean Pain Improvement: Open-Label Phase
At Week 52, the mean decrease in pain score from
baseline was 1.08 (95% CI 1.52 to 0.65) for
patients who were originally randomized toTable
Mean Change From Baseline in Pain Score by Tr
Time Point Total Number of Patients
Mean
Onabotulinu
ITT population
Week 12 246 0.77 (
Week 24c 240 0.78 (
Patients with BL pain $4
Week 12 113 2.10 (
Week 24c 112 2.45 (
BL ¼ baseline; SC ¼ standard care; ITT ¼ intent-to-treat.
aLeast squares means (adjusted for covariate) on change from baseline pain score
bComparison of changes from baseline in pain scores by analysis of covariance wi
cWeek 24 for patients with a single injection or 10 weeks after the second injectioonabotulinumtoxinA þ SC (Fig. 1). This is a small in-
cremental improvement over the pain reduction
achieved during the double-blind period. In contrast,
patients who were originally randomized to
placebo þ SC showed greater relative reduction in
pain after receiving onabotulinumtoxinA during the
open-label phase (0.67, 95% CI 1.12 to 0.22;
Fig. 1). A similar trend in reduction in pain from base-
line over the open-label phase was also seen in the
pain subgroup patients of the two initial treatment
arms (onabotulinumtoxinA þ SC [2.86, 95% CI
3.62 to 2.09] versus placebo þ SC [2.27, 95%
CI 2.99 to 1.55]).
Patients Achieving$30% and$50% Reductions in
Pain From Baseline: Open-Label Phase
High proportions of onabotulinumtoxinA- and
placebo-treated patients in the pain subgroup
continued to achieve $30% or $50% reductions in
pain by Week 52. Similar to the results for mean
change from baseline pain, the proportion of patients
in the pain subgroup achieving $30% or $50%
reduction in pain from baseline by Week 52 was gener-
ally maintained in the subgroup originally random-
ized to onabotulinumtoxinA þ SC and greatly
increased in the placebo þ SC arm after receiving ona-
botulinumtoxinA. For instance, among patients who
received placebo þ SC during the double-blind phase
followed by onabotulinumtoxinA during the open-
label phase, the proportion of patients who achieved
$30% reduction in pain significantly increased from
30.0% (15/50) to 52.0% (26/50) at Week 52
(P < 0.05), whereas the corresponding difference
among patients who received onabotulinumtoxinA
throughout was not significant (64.3% [27/42] and
59.5% [25/42], respectively; P ¼ 0.480). The results
for achievement of $50% reduction in pain were
similar: in patients that received placebo during the
double-blind phase followed by open-label onabotuli-
numtoxinA, the proportion was 24.0% (12/50) at
Week 24, which increased to 46.0% (23/50) at Week
52 (P < 0.05), whereas the corresponding difference2
eatment Arm During Double-Blind Treatment
Change From BL in Pain Scorea (95% CI)
P-valuebmtoxinA þ SC Placebo þ SC
1.14, 0.40) 0.13 (0.51, 0.24) 0.019
1.22, 0.34) 0.13 (0.58, 0.31) 0.043
2.69, 1.51) 1.21 (1.77, 0.65) 0.033
3.19, 1.71) 1.70 (2.39, 1.02) 0.145
s.
th baseline pain values as a covariate and treatment as main effect.
n.
Fig. 1. Mean changea from baseline in PNRS score during the double-blind and open-label treatment phases. Error bars
represent 95% CIs. aLeast squares means (adjusted for covariate) on change from baseline pain scores. bP < 0.05 versus pla-
cebo. OnabotA ¼ onabotulinumtoxinA; PNRS ¼ Pain Numeric Rating Scale.
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throughout was not significant (50.0% [21/42] vs.
57.1% [24/42]; P ¼ 0.317).
Pain Interference With Work
Among patients with moderate-to-extreme work
interference caused by pain at baseline, in the
onabotulinumtoxinA þ SC arm, 64.4% (29/45) and
26.7% (12/45) had a $1- and $2-point decrease in
pain interference score at Week 12, respectively,
compared with 42.9% (24/56; P < 0.05) and 23.2%
(13/56; P ¼ 0.689) in the placebo þ SC arm (Fig. 3).
For the same subgroup, the proportion of patients
with a $1-point improvement in pain interference
score at Week 24 or 10 weeks after the second injectionFig. 2. Proportions of patients who achieved $30% and $50% r
10 weeks after second injection, and at Week 52 in the subgroup
aP < 0.05 versus placebo. OnabotA ¼ onabotulinumtoxinA.was higher in the onabotulinumtoxinA þ SC arm than
that in the placebo arm (P < 0.05). At the same
time point, the proportion of patients in the
onabotulinumtoxinAþ SC armwho achieved$2-point
improvement in pain interference scores was higher
than those receiving placebo (38.1% [16/42] vs.
20.8% [11/53]; P ¼ 0.063). At Week 52, most patients
in the group originally randomized to
onabotulinumtoxinA þ SC maintained a $1-point
improvement in work interference (73.3% [33/45]).
Similarly, in the original placebo arm, the percentage
of patients maintaining a $1-point improvement in
work interference was maintained at 52 weeks (54.4%
[31/57]). The percentage of patients achieving a
$2-point reduction in work interference scores causedeductions in pain score from baseline at Week 12, Week 24/
of patients with baseline pain scores $4 (‘‘pain subgroup’’).
Fig. 3. Proportions of patients with $1- and $2-point reductions in pain interference with work from baseline. Pain interfer-
ence with work was measured using the SF-12 Item #5. Patients with a pain interference score of 3e5 (moderate to severe) at
baseline were evaluated. aP < 0.05 versus placebo. OnabotA ¼ onabotulinumtoxinA; SF-12 ¼ Short Form-12.
Table 3
Exploratory Analyses: Proportions of Patients Achieving
Secondary Goals Related to Pain Relief According to
Patient Rating on the Goal Attainment Scale
Time Point
Proportion of Patients Achieving
Goals; n/N, (%)
P-valueaOnabotulinumtoxinA þ SC Placebo þ SC
Overall
Week 12 8/15 (53.3) 7/21 (33.3) 0.230
Week 24b 9/13 (69.2) 11/23 (47.8) 0.214
Lower-limb pain
Week 12 3/8 (37.5) 3/9 (33.3) 1.000
Week 24b 5/7 (71.4) 5/9 (55.6) 0.633
Shoulder pain
Week 12 5/8 (62.5) 4/10 (40.0) 0.637
Week 24b 4/7 (57.1) 4/11 (36.4) 0.630
SC ¼ standard care.
aComparison between onabotulinumtoxinA and placebo at each visit based
on c2 test or Fisher exact test as appropriate.
bWeek 24 for patients with a single injection or 10 weeks after the second
injection.
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originally randomized to onabotulinumtoxinA þ SC
(42.2% [19/45]). In the original placebo arm, the
percentage of patients achieving a $2-point reduction
in work interference scores increased to 33.3%
(19/57) at Week 52 after receiving open-label
onabotulinumtoxinA.
Exploratory Analyses
Pain-Related Goal Achievement. Among patients
who chose ‘‘pain relief’’ as their secondary goal
(n ¼ 46 [ITT]), greater proportions in the
onabotulinumtoxinA þ SC group achieved the goal
compared with those treated with placebo þ SC at
Weeks 12 and 24 (or 10 weeks after second injection);
although, the differences were not significant
(Table 3). Patient-rated goal achievement was also
numerically but not statistically higher during the
double-blind phase among those originally random-
ized to onabotulinumtoxinA who chose pain relief
goals associated with lower limb and shoulder pain.
During open-label treatment, the proportion of
patients achieving their secondary goals related
to pain relief at Week 52 was 85.7% (12/14) in the
group that was originally randomized to
onabotulinumtoxinA þ SC and 66.7% (16/24) in
the group that was originally randomized to
placebo þ SC group and received onabotulinumtoxi-
nA during the open-label phase.
Correlations Between Muscle Tone and Pain Scores.
Exploratory analysis revealed a weak correlation
between pain reduction and improvement in muscle
tone at Week 12 (r ¼ 0.146; Fig. 4) among patients
with moderate-to-severe spasticity at baseline
($1 item on the REPAS with a spasticity score $1across the relevant joints). A weak correlation also
was observed at Week 52 (r ¼ 0.105; Fig. 4) among
patients who were originally randomized to
placebo þ SC.Discussion
BEST is a unique study that evaluated the efficacy of
onabotulinumtoxinA in a setting that reflects usual
clinical practice within a controlled trial. The patient
population included patients with upper and/or
lower-limb spasticity and, to our knowledge, is the
first randomized, placebo-controlled trial to demon-
strate that onabotulinumtoxinA effectively reduces
pain in PSS. Our findings showed significant and
clinically meaningful reductions in pain with
onabotulinumtoxinA þ SC, which were sustained
Fig. 4. Exploratory analyses. Correlation between change in pain and change in REPAS-26 total score at Week 12 in patients
with moderate-to-severe spasticity at baseline and at Week 52 among patients with moderate-to-severe spasticity that received
placebo þ SC during the double-blind portion of the study, followed by onabotulinumtoxinA þ SC during the open-label
phase. REPAS ¼ REsistance to PAssive movement Scale; SC ¼ standard care.
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effect of onabotulinumtoxinA was observed to be
greater among patients with moderate-to-severe base-
line pain. The pain response among patients who
continued to receive onabotulinumtoxinA after
double-blind treatment remained largely stable, and
significantly increased in those who had received
placebo during double-blind followed by open-label
onabotulinumtoxinA. Together, these results suggest
that in addition to reducing muscle tone, onabotuli-
numtoxinA provided additional treatment benefit by
significantly relieving PSS pain.
Our results support the findings of the majority of
studies of onabotulinumtoxinA for treatment of PSS.
However, in one study, onabotulinumtoxinA failed to
produce significant differences in pain compared
with placebo, possibly owing to the size (n ¼ 39).28
Another randomized, double-blind comparative study
in PSS patients with hemiplegic shoulder pain found
that onabotulinumtoxinA may provide more pain re-
lief (PNRS score, 7.9  0.3 at baseline vs. 3.2  0.5
at Week 12) than triamcinolone acetonide (PNRS
score, 7.6  0.5 at baseline vs. 5.2  0.8 at Week 12;n ¼ 29; P ¼ 0.064).1 Uncontrolled studies have shown
beneficial effects of onabotulinumtoxinA on
pain.8,17,18,29e31
In a prospective multicenter study in patients with
upper motor neuron syndrome and pain as the pri-
mary spasticity-related complaint, one onabotulinum-
toxinA injection provided pain relief in 90% (54/60)
of patients.8 In two smaller studies that evaluated the
effects of onabotulinumtoxinA in patients with upper
or lower-limb spasticity, 28/31 and 30/32 patients with
local pain, respectively, experienced pain relief after
onabotulinumtoxinA.17,18 An open-label study of ona-
botulinumtoxinA for treatment of upper-limb spas-
ticity demonstrated a $1-point improvement in pain
(four-point Likert scale) in 25%e33% of patients.29
OnabotulinumtoxinA has also improved pain in un-
controlled studies of spastic foot drop.30,31
The present study demonstrated that
onabotulinumtoxinA þ SC significantly reduced pain
interference with work, which was maintained
through Week 52. More patients in the onabotulinum-
toxinA group achieved $1- and $2-point decreases in
pain interference scores. This is promising, as the
24 Vol. 52 No. 1 July 2016Wissel et al.symptoms associated with PSS have previously been
shown to affect patients’ abilities to work.32 A survey
of 589 PSS patients found that almost 60% of respon-
dents were unemployable and 29% reported that their
work was limited to some extent by their condition.33
Furthermore, patients with spasticity have rated pain
relief as one of their important goals of therapy.34,35
Therapies that reduce pain may have an impact on
HRQoL, although this needs further investigation.
The proportion of PSS patients in BEST reporting
moderate-to-severe baseline pain (47%) is higher than
the estimates (21%e30%) reported in previous post-
stroke pain studies.3,4 However, the estimate from
BEST is from patients with PSS, whereas other studies
included a chronic stroke population with/without
spasticity. Prevalence estimates could vary because of
underlying differences in patient characteristics (e.g.,
age, sensory/motor impairment), as well as differences
in the pain scale and recall periods in different studies.
The high prevalence of baseline pain observed in BEST
implies that there could be significant humanistic
burden due to pain in this population.
Exploratory analyses revealed that onabotulinum-
toxinA treatment resulted in trends toward greater
goal achievement among patients who chose pain
relief-associated goals, regardless of the anatomical
location of the pain. These results should be inter-
preted with caution because they are based on small
sample and lacked adequate statistical power. Another
limitation of the exploratory GAS analyses was that
pain goals differed for each patient, which may have
caused inconsistency in pain measurement and intro-
duced difficulty in interpreting the results of pain
relief using the GAS scoring. Furthermore, goal
achievement may have been affected by whether pri-
mary goals were achieved.
Peak effect of onabotulinumtoxinA on reducing
muscle tone generally occurs around 6e8 weeks after
injection12,13,15,36,37; significant pain reductions were
observed at Week 12 in BEST, suggesting maintenance
of benefit. The precise contribution whereby onabotu-
linumtoxinA reduces pain in patients with spasticity is
unknown. Clinically, the onabotulinumtoxinA effect
was explored by evaluating the association between
pain and REPAS scores. The lack of strong correlation
observed suggests that pain reduction was only weakly
associated with muscle tone improvement. This inter-
pretation is based on the REPAS scale, which is a total
score of muscle tone assessments across upper and
lower limbs and not restricted to the treated muscles.
Another study showed that there is no direct correla-
tion between the Ashworth scores of muscles treated
and PNRS, lending support to our observation.38 Simi-
larly, patients treated with onabotulinumtoxinA for
motor disability and pain associated with dystoniaexperienced significant pain relief, which preceded
improvement in muscle activity.39 In a related
example, patients receiving onabotulinumtoxinA for
focal dystonias reported pain relief as a major benefit,
and frequently requested re-injection to alleviate pain
before recurrence of the postural symptoms and
before their neurological condition returned to
baseline.40
Together, these findings are consistent with the
known muscle relaxation and antinociceptive mecha-
nisms of onabotulinumtoxinA and suggest a direct
antinociceptive effect resulting in the clinical pain re-
lief experienced by study participants. The effect of
onabotulinumtoxinA on pain is thought to be medi-
ated by two mechanisms. The first is through a non-
muscle mechanism by which onabotulinumtoxinA
blocks the release of neurotransmitters and neuropep-
tides from nociceptive terminals of primary afferent
nerve fibers41e43 in addition to interfering with sur-
face expression of pain receptors and ion channels
on nerve membranes.44 This blockade causes an indi-
rect reduction of central sensitization through the
reduction of peripheral nerve overactivity.45,46 The
other mechanism involves the anticholinergic effects
at neuromuscular junctions, which directly ameliorate
excessive contractions, and inhibit the painful spasms
that contribute to pain in joints and tendons.47
There are some limitations of this study. As assess-
ment of pain relief was not themain objective, the study
did not use established methods typical of pain studies
(e.g., pain diaries). This limitation prevented investiga-
tors from identifying and documenting the pain source
or exact location. Spasticity may have been a contrib-
utor, but the exact reason for pain is unclear. The
dose and selection of target muscles varied between
patients because of the area of focal spasticity and vari-
ability between physicians. This study used the SF-12 to
identify the impact of pain on work interference,
although generic instruments may not be optimal for
evaluating changes in HRQoL in PSS patients. Finally,
there may have been selection bias through patient
loss during the open-label phase. Although retention
was high into the open-label phase (224/273, 82%),
and equally distributed between patients treated with
onabotulinumtoxinA (n ¼ 113) or placebo (n ¼ 111)
in the double-blind phase, the patients continuing
may have been selectively responsive to treatment.
Although the precise mechanism of action is un-
known, the present study suggests that the effects of
onabotulinumtoxinA on pain and muscle tone may
be independent of each other and mediated by
different mechanisms of action. In addition, the re-
sults suggest that onabotulinumtoxinA þ SC treat-
ment decreased pain interference with work. When
combined with the improvement in muscle tone,
Vol. 52 No. 1 July 2016 25BOTOX for Post-Stroke Spasticity PainonabotulinumtoxinA may have the potential to
improve the lives of affected patients with PSS by
reducing pain. Future studies should confirm the
effectiveness of onabotulinumtoxinA in the treatment
of pain syndromes in patients with PSS.Disclosures and Acknowledgments
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